Bioactivity | Nimustine is a nitrosourea alkylating agent. Nimustine induces cell apoptosis, and activates DNA damage response and MAPK signaling. Nimustine shows anti-cancer effects, it can be used for the research of cancer[1][2]. |
Invitro | Nimustine (50 μM; 72-120 h) causes cell death by inducing cell apoptosis[1].Nimustine (50 μM; 24-96 h) activates the DNA damage response pathway[1].Nimustine (50 μM; 24-120 h) activates MAPK signaling in glioma cells[1]. Apoptosis Analysis[1] Cell Line: |
In Vivo | Nimustine (15 four times a week and 30 mg/kg twice with an interval of 2 weeks; i.v.) effectively inhibits tumor growth and the higher dose is more effective[2]. Animal Model: |
Name | Nimustine |
CAS | 42471-28-3 |
Formula | C9H13ClN6O2 |
Molar Mass | 272.69 |
Transport | Room temperature in continental US; may vary elsewhere. |
Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
Reference | [1]. Tomicic MT, et al. Apoptosis induced by temozolomide and nimustine in glioblastoma cells is supported by JNK/c-Jun-mediated induction of the BH3-only protein BIM. Oncotarget. 2015 Oct 20;6(32):33755-68. [2]. Shimizu F, et al. Effects of combined treatment with nimustine hydrochloride and radiation on solid FM3A tumor in mice. Jpn J Cancer Res. 1987 Jul;78(7):756-62. |